Mechanistically, Kremen2 may exert its oncogenic effect by interacting with SOCS3 and blocking the ubiquitin-dependent EGFR degradation, thereby sustaining the EGFR-mediated cancer signaling pathways and promoting cell proliferation and metastasis of NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.